NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT02318901 2019-10-21PembroMabWestern Regional Medical CenterPhase 1/2 Terminated16 enrolled 6 charts
NCT01705340 2013-09-30Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 1 Terminated60 enrolled
NCT00004074 2013-02-28Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNational Cancer Institute (NCI)Phase 1 Completed15 enrolled
NCT00005842 2013-02-11Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerNational Cancer Institute (NCI)Phase 1 Completed24 enrolled